Immuno US, Inc. Report issue

For profit Phase 1
Founded: San Diego CA United States (1992)
Status: Acquired by Baxalta (1997) → now Takeda (2018)

Organization Overview

First Clinical Trial
1999
NCT00000957
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1999

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Immuno-US

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

HIV Infections (Phase 1)

HIV Seropositivity (Phase 1)

Vaccinia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 5
  • # of Trial APIs: 5